Updates
What has actually happened.
Dated entries, newest first. An item goes up once it has happened and been confirmed. Conversations, applications and plans stay off this page until they are done.
-
Accepted into the NSF I-Corps Medical Device Tech cohort. Cohort dates: September 28 to October 28, 2026. I-Corps is structured customer discovery: interviews with the nurses, physicians, nurse leaders and hospital staff who would use or buy a product like Pathos Vigil.
-
Accepted as a member of SyracuseCoE. Intuitive Pathos was accepted as a new member of SyracuseCoE, the Syracuse Center of Excellence.
-
Signed two engagements with TDO. TDO, Central New York’s Manufacturing Extension Partnership center, signed two engagements with Intuitive Pathos, fully executed in August 2026: an ISO 13485 design and development procedure, which is under way, and regulatory support for Pathos Vigil, which has not yet started.
What this page leaves out
Pathos Vigil is an investigational medical device. It has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority, and it is not available for sale or clinical use. Nothing here is a claim of clinical performance, a partnership that has not been agreed, or funding that has not been received.